Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

To join this study, you must be at least 18 years old and in reasonably good health, as assessed by a doctor. You will need to sign a consent form, showing you understand the study and agree to take part.

If you have Non-Hodgkin Lymphoma, your cancer must have come back or not responded to at least two previous treatments, and one of these treatments must have included a specific type of immunotherapy (an αCD20 antibody). Your cancer also needs to be measurable on a scan. If you have B-cell Acute Lymphoblastic Leukaemia, your cancer needs to be active in your bone marrow.

There are also some things that would prevent you from joining. For example, if you have severe allergies to ingredients in the study medicine, certain serious infections, a history of other specific cancers recently, active cancer spread to your brain or spine, or certain active autoimmune diseases. You also can't be taking certain medications that suppress your immune system.

If you decide to take part in this study, you will receive the study medicine, PIT565. The way it's given (for example, as an injection or through a drip) and how often will be decided as the study progresses, as this is part of what the researchers are trying to figure out. You will have regular appointments at the hospital, where the study team will monitor your health very closely. This will involve physical examinations, blood tests, scans, and other checks to see how you are responding to the medicine and to look for any side effects. The total duration of your participation will depend on how you respond to the treatment and the study plan, but you will be informed about the expected length.